Abstract
Objective
Donor-derived carbapenem-resistant Klebsiella pneumoniae (CRKP) infection has recently emerged as a critical early complication after renal transplantation. Although CRKP is usually sensitive to tigecycline, monotherapy with this drug is often less than effective. We investigated the efficacy of a combined regimen of tigecycline with high-dose, extended-infusion meropenem in the treatment of donor-derived CRKP infection after kidney transplantation.
Methods
From Jan. 2016 to Dec. 2017, a total of 12 CRKP isolates were detected from cultures of the organ preservation solution used for soaking the donor kidneys at our institute. Probable or possible donor-derived infection (DDI) was identified in 8 transplant recipients. Clinical data were retrospectively analyzed.
Results
Klebsiella pneumoniae carbapenemase-2 (KPC-2)-producing CRKP was reported to be positive in organ preservation solution cultures at 3.5±0.9 days after transplantation, leading to surgical site (n=3), urinary tract (n=4), and/or bloodstream (n=2) infections in 8 recipients. The drug susceptibility tests showed that CRKP was sensitive to tigecycline, but resistant to meropenem. In 7 patients who received tigecycline combined with high-dose extended-infusion meropenem, DDIs were successfully cured. The length of hospital stay was 31 (18–129) days, and the serum creatinine at discharge was 105.8±16.7 µmol/L. The one remaining patient who received tigecycline combined with intravenous-drip meropenem died of septic shock. A median follow-up of 43 months (33–55) showed no recurrence of new CRKP infection in the 7 surviving recipients.
Conclusion
It was suggested that a prompt and appropriate combination therapy using tigecycline with high-dose extended-infusion meropenem is effective in treating donor-derived KPC-2-producing CRKP infection after renal transplantation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Fishman JA, Grossi PA. Donor-derived infection–the challenge for transplant safety. Nat Rev Nephrol, 2014,10(11):663–672
Ison MG, Grossi P, AST Infectious Diseases Community of Practice. Donor-derived infections in solid organ transplantation. Am J Transplant, 2013,13(Suppl 4):22–30
Kaul DR. Donor-derived infection: epidemiology and outcomes. Curr Infect Dis Rep, 2012,14(6):676–682
Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA, 2008, 300(24):2911–2913
Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis, 2014,58(9):1274–1283
Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis, 2012, 14(2):198–205
Mularoni A, Bertani A, Vizzini G, et al. Outcome of Transplantation Using Organs From Donors Infected or Colonized With Carbapenem-Resistant Gram-Negative Bacteria. Am J Transplant, 2015,15(10):2674–2682
Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens. Antimicrob Agents Chemother, 2012,56(4):2108–2113
Bai XR, Liu JM, Jiang DC, et al. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies. J Chemother, 2018,30(3):172–178
van Duin D, van Delden C, Practice ASTIDCo. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant, 2013,13(Suppl 4):31–41
Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoiae: importance of combination therapy. Clin Infect Dis, 2012,55(7):943–950
Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother, 2012,56(4):2108–2113
Souli M, Karaiskos I, Masgala A, et al. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis, 2017, 36(7):1305–1315
Garzoni C, Ison MG. Uniform definitions for donor-derived infectious disease transmissions in solid organ transplantation. Transplantation, 2011,27;92(12):1297–300
Simkins J, Muggia V, Cohen HW, et al. Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients: a case-control study. Transpl Infect Dis, 2014,16(5):775–782
Wang Y, Lei H, Zhang Y, et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae bloodstream infections after renal transplantation from donation after cardiac death in a Chinese hospital: a case series analysis. Antimicrob Resist Infect Control, 2018, 7:66
Cunha BA, Baron J, Cunha CB. Monotherapy with High-Dose Once-Daily Tigecycline is Highly Effective Against Acinetobacter baumanii and other Multidrug-Resistant (MDR) Gram-Negative Bacilli (GNB). Int J Antimicrob Agents, 2018,52(1):119–120
Baron J, Cai S, Klein N, et al. Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness. J Clin Med, 2018,9;7(3):49
Srinivas NR. Tigecycline and cyclosporine interactionan interesting case of biliary-excreted drug enhancing the oral bioavailability of cyclosporine. Eur J Clin Pharmacol, 2009,65(5):543–544
Pavan M, Chaudhari AP, Ranganth R. Altered bioavailability of tacrolimus following intravenous administration of tigecycline. Am J Kidney Dis, 2011, 57(2):354
Bias TE, Malat GE, Lee DH, et al. Clinical outcomes associated with carbapenem resistant Klebsiella pneumoniae (CRKP) in abdominal solid organ transplant (SOT) recipients. Infect Dis, 2018,50(1):67–70
van Duin D, Lok JJ, Earley M, et al. Antibacterial Resistance Leadership G. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis, 2018,66(2):163–171
Acknowledgments
We thank Dr. Deborah McClellan for editorial assistance.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
All the authors declared no competing interests. The clinical activities being reported are consistent with the principles of the declaration of Istanbul as outlined in the “Declaration of Istanbul on Organ Trafficking and Transplant Tourism”.
Additional information
This project was supported by grants from Non-Profit Central Research Institute Fund of Chinese Academy of Medical Science (No. 2018PT32018) and Hubei Science and Technology Plan (No. 2017ACA096).
Rights and permissions
About this article
Cite this article
Wang, Zq., Guo, Zl., Feng, H. et al. Treatment of Donor-derived Carbapenem-resistant Klebsiella pneumoniae Infection after Renal Transplantation with Tigecycline and Extended-infusion Meropenem. CURR MED SCI 41, 770–776 (2021). https://doi.org/10.1007/s11596-021-2397-z
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-021-2397-z